Eledon Pharmaceuticals (ELDN) Competitors $2.87 +0.14 (+5.13%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$2.83 -0.04 (-1.39%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELDN vs. BCAX, KALV, GOSS, SNDL, SVRA, ARVN, MBX, ARCT, AQST, and ERASShould you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Bicara Therapeutics (BCAX), KalVista Pharmaceuticals (KALV), Gossamer Bio (GOSS), SNDL (SNDL), Savara (SVRA), Arvinas (ARVN), MBX Biosciences (MBX), Arcturus Therapeutics (ARCT), Aquestive Therapeutics (AQST), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry. Eledon Pharmaceuticals vs. Its Competitors Bicara Therapeutics KalVista Pharmaceuticals Gossamer Bio SNDL Savara Arvinas MBX Biosciences Arcturus Therapeutics Aquestive Therapeutics Erasca Eledon Pharmaceuticals (NASDAQ:ELDN) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability. Is ELDN or BCAX more profitable? Bicara Therapeutics' return on equity of -21.67% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eledon PharmaceuticalsN/A -92.51% -38.31% Bicara Therapeutics N/A -21.67%-20.89% Do insiders & institutionals believe in ELDN or BCAX? 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 12.3% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 15.5% of Bicara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better valuation and earnings, ELDN or BCAX? Bicara Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEledon PharmaceuticalsN/AN/A-$36.18M-$1.17-2.45Bicara TherapeuticsN/AN/A-$68M-$3.17-5.68 Does the media favor ELDN or BCAX? In the previous week, Bicara Therapeutics had 5 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 7 mentions for Bicara Therapeutics and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.02 beat Bicara Therapeutics' score of 0.59 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ELDN or BCAX? Eledon Pharmaceuticals presently has a consensus target price of $10.00, indicating a potential upside of 248.43%. Bicara Therapeutics has a consensus target price of $31.86, indicating a potential upside of 76.99%. Given Eledon Pharmaceuticals' higher probable upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Bicara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40Bicara Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 SummaryBicara Therapeutics beats Eledon Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELDN vs. The Competition Export to ExcelMetricEledon PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.48M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-2.4521.5785.5627.61Price / SalesN/A271.42535.65201.06Price / CashN/A47.1237.9261.55Price / Book2.7310.1413.036.76Net Income-$36.18M-$52.31M$3.30B$275.88M7 Day Performance3.99%5.14%4.35%2.81%1 Month Performance7.09%14.68%9.50%9.24%1 Year Performance8.71%30.98%85.16%35.42% Eledon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELDNEledon Pharmaceuticals2.3327 of 5 stars$2.87+5.1%$10.00+248.4%+9.5%$163.48MN/A-2.4510Positive NewsAnalyst ForecastGap UpBCAXBicara Therapeutics2.324 of 5 stars$13.87+18.4%$32.25+132.5%-20.2%$638.93MN/A-4.3832News CoverageInsider TradeHigh Trading VolumeKALVKalVista Pharmaceuticals3.8346 of 5 stars$12.21-1.5%$26.43+116.5%+2.5%$626.49MN/A-3.10100Analyst ForecastGOSSGossamer Bio3.9887 of 5 stars$2.82+4.4%$8.50+201.4%+137.3%$613.93M$114.70M-4.55180Analyst ForecastSNDLSNDL3.1166 of 5 stars$2.74+17.6%$4.50+64.2%+35.6%$612.27M$671.81M-10.152,516Analyst ForecastHigh Trading VolumeSVRASavara2.7093 of 5 stars$3.52flat$7.50+113.1%-8.2%$608.39MN/A-7.0420Trending NewsAnalyst ForecastARVNArvinas3.0062 of 5 stars$8.53+3.1%$16.18+89.7%-62.2%$607.16M$263.40M-8.45420Analyst ForecastMBXMBX BiosciencesN/A$17.94+2.5%$39.88+122.3%N/A$602.68MN/A-3.9536ARCTArcturus Therapeutics2.8015 of 5 stars$18.78-15.3%$50.57+169.3%-5.7%$602.03M$109.80M-8.42180Analyst ForecastHigh Trading VolumeAQSTAquestive Therapeutics2.4949 of 5 stars$5.65-5.7%$10.29+82.0%+26.1%$597.34M$57.56M-8.07160News CoverageAnalyst ForecastERASErasca2.6586 of 5 stars$2.11+1.4%$3.71+76.0%-3.6%$590.03MN/A-4.69120News CoverageAnalyst ForecastOptions Volume Related Companies and Tools Related Companies BCAX Competitors KALV Competitors GOSS Competitors SNDL Competitors SVRA Competitors ARVN Competitors MBX Competitors ARCT Competitors AQST Competitors ERAS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELDN) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
